-
Incyte inks $750M deal for immune and neuro biotech Escient
23 Apr 2024 13:41 GMT
… San Diego biotech Escient Pharmaceuticals and its pipeline of early-stage drug candidates … .
The deal gives the Delaware-based drugmaker access …
-
PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of Legal
23 Apr 2024 16:46 GMT
… the biotechnology industry and in academia, including in drug development, … Sage Therapeutics, Inc.
About PharmaEssentia
PharmaEssentia (TWSE: 6446), headquartered in … U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its …
-
Response Pharmaceuticals’ Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial
23 Apr 2024 12:57 GMT
… (AIWG) is a drug-induced epidemic within the … in high rates of medication discontinuation or a change … to a less efficacious medication, and often leads to … Response Pharmaceuticals
Response Pharmaceuticals is a clinical-stage biotechnology company focused …
-
Upcoming US Pharma and Biotech Summit Spotlights Innovation, Challenges in Healthcare
23 Apr 2024 13:41 GMT
… the Financial Times US Pharma and Biotech Summit will take place … profound implications for the drug industry.
Tackling America’s … past two decades.
Funding pharma and biotech innovation: This panel … costs of funding experimental drugs and how companies come …
-
Krystal Biotech gets grant for pharmaceutical composition for cancer treatment using recombinant HSV-1 virus
23 Apr 2024 13:40 GMT
… ’s company profile on Krystal Biotech, Oncolytic viruses was a key … area identified from patents. Krystal Biotech';s grant share as … Biotech Inc
A recently granted patent (Publication Number: US11918660B2) discloses a pharmaceutical composition …
-
MAIA Biotechnology Announces $1.00 Million Private Placement
23 Apr 2024 13:09 GMT
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA … or other jurisdiction.
About MAIA Biotechnology, Inc.
MAIA is a targeted … of potential first-in-class drugs with novel mechanisms of … and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
View …
-
Quotient Sciences new platform disrupts conventional drug development processes
23 Apr 2024 12:29 GMT
… came to rising inflation impacting biotech funding and M&A … of a return to increasing biotech industry funding to support the … of our flagship Translational Pharmaceutics platform for drug development remains a key …
-
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr.…
23 Apr 2024 12:00 GMT
… small molecule drug discovery at leading biotech companies SAN … to several successful marketed drugs will be invaluable … , including those supporting successful drugs Harvoni and Veklury. Dr … graduate studies in the Pharmacology Department at Yale University. …
-
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
23 Apr 2024 12:00 GMT
… the IL-12 fused antibody drug conjugate PDS01ADC may represent in … , click here. About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy … of IL-12 fused antibody drug conjugate (ADC) PDS01ADC and T …
-
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
23 Apr 2024 12:00 GMT
… , 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a … biotechnology company developing therapeutics to slow, … the uncertainties inherent in the drug development process, and risks relating …